Robert Shorr, Ph.D. will act as an Executive Consultant and serves as Chairman of Prolong Pharmaceuticals Scientific Advisory Board. Dr. Shorr is the author of over 150 scientific publications in the areas of drug delivery, diagnostics, reagents and therapeutic agents. He has over 70 patents issued or pending. He served as Vice President of Science and Technology at Enzon, Inc. from 1991 to 1998. At Enzon, Dr. Shorr was instrumental in taking Enzon's blood substitute program (PEG-Hemoglobin) through Phase I clinical trials and bringing PEG-Intron to market. Prior to joining Enzon, Dr. Shorr held management positions at AT Biochem and Smith Kline and French. He is currently a Principal Partner in Altira Capital and Consulting LLC and Director of Business Development at the State University of New York at Stony Brook Center for Advanced Technology. Dr. Shorr received a B.S. in Biology at the State University of New York at Buffalo and a Ph.D. in Biochemistry from the University of London, Imperial College of Science & Technology. |